CytoSorbents (STU:HQE) Cyclically Adjusted FCF per Share: €-7.91 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HQE CytoSorbents Corp STU:HQE
45 GF Score
Price €5.92
GF Value €16.19
! 5 Warning Signs
View Full Analysis

What is CytoSorbents Cyclically Adjusted FCF per Share?

CytoSorbents STU:HQE 45 Cyclically Adjusted FCF per Share is €-7.91 as of Jun. 2026. GuruFocus rates STU:HQE with a GF Score™ of 45/100 and a GF Value™ of €16.19. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

CytoSorbents's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.175. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-7.91 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 1.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -1.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 9.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of CytoSorbents was 24.10% per year. The lowest was -4.70% per year. And the median was 6.50% per year.

As of today (2026-09-11), CytoSorbents's current stock price is €5.92. CytoSorbents's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-7.91. CytoSorbents's Cyclically Adjusted Price-to-FCF of today is .


CytoSorbents  (STU:HQE) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


CytoSorbents Cyclically Adjusted FCF per Share Related Terms


CytoSorbents Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for CytoSorbents's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoSorbents Cyclically Adjusted FCF per Share Chart

CytoSorbents Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.41 -7.90 -8.50 -8.90 -7.93

CytoSorbents Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.37 -7.67 -7.93 -8.03 -7.91

STU:HQE vs LFWD, GTHP, PMI: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, CytoSorbents's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoSorbents Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CytoSorbents's Cyclically Adjusted Price-to-FCF falls into.


STU:HQE
45GF Score
CytoSorbents Corp STU:HQE
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoSorbents Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytoSorbents's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.175/333.9520*333.9520
=-0.175

Current CPI (Jun. 2026) = 333.9520.

CytoSorbents Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -1.850 241.428 -2.559
201612 -0.872 241.432 -1.206
201703 -1.596 243.801 -2.186
201706 -1.416 244.955 -1.930
201709 -1.612 246.819 -2.181
201712 -0.580 246.524 -0.786
201803 -1.471 249.554 -1.968
201806 -2.102 251.989 -2.786
201809 -1.587 252.439 -2.099
201812 -1.672 251.233 -2.223
201903 -2.598 254.202 -3.413
201906 -1.919 256.143 -2.502
201909 -3.084 256.759 -4.011
201912 -2.498 256.974 -3.246
202003 -1.970 258.115 -2.549
202006 0.698 257.797 0.904
202009 -1.498 260.280 -1.922
202012 -0.501 260.474 -0.642
202103 -1.140 264.877 -1.437
202106 -1.152 271.696 -1.416
202109 -2.007 274.310 -2.443
202112 -2.902 278.802 -3.476
202203 -3.726 287.504 -4.328
202206 -5.499 296.311 -6.198
202209 -3.435 296.808 -3.865
202212 -2.387 296.797 -2.686
202303 -1.613 301.836 -1.785
202306 -2.835 305.109 -3.103
202309 -2.296 307.789 -2.491
202312 -2.614 306.746 -2.846
202403 -1.676 312.332 -1.792
202406 -1.681 314.175 -1.787
202409 -0.914 315.301 -0.968
202412 -0.860 315.605 -0.910
202503 -1.070 319.799 -1.117
202506 -0.423 322.561 -0.438
202509 -0.685 324.800 -0.704
202512 -1.412 324.054 -1.455
202603 -0.340 330.213 -0.344
202606 -0.175 333.952 -0.175

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-7.91 mean?
CytoSorbents (STU:HQE) has a Cyclically Adjusted FCF per Share of €-7.91 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CytoSorbents and its competitors.
Is CytoSorbents' Cyclically Adjusted FCF per Share too high?
CytoSorbents' current Cyclically Adjusted FCF per Share is €-7.91. Overall, CytoSorbents has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does CytoSorbents' Cyclically Adjusted FCF per Share compare to LFWD and GTHP?
CytoSorbents' Cyclically Adjusted FCF per Share of €-7.91 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CytoSorbents and its competitors. CytoSorbents's current Cyclically Adjusted FCF per Share is €-7.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoSorbents stock overvalued right now?
CytoSorbents (STU:HQE) has a current Cyclically Adjusted FCF per Share of €-7.91. The stock's GF Value™ is €16.19, compared to a current price of €5.92 — trading 63.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-7.91. CytoSorbents' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For CytoSorbents (STU:HQE), the current Cyclically Adjusted FCF per Share is €-7.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytoSorbents (STU:HQE) Overvalued in 2026?

Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued. The current stock price of €5.92 is trading 63.4% below its estimated GF Value™ of €16.19.

Key valuation signals for STU:HQE:

  • Cyclically Adjusted FCF per Share: €-7.91
  • GF Value™: €16.19 vs. price of €5.92 (63.4% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STU:HQE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytoSorbents Business Description

Other Exchanges CTSO:USA
Address 305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
45GF Score

Get the complete analysis for STU:HQE

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.92
Price
€16.19
GF Value